New HIV drugs set to be cheaper
A new single-dose, two-drug regimen to treat HIV, dolutegravir and rilpivirine, is to be listed on the PBS.
The 1 December listing will substantially reduce the cost of the drugs for patients, which currently retail at $10,800 a year.
The step comes as the Federal Government launches Australia’s eighth national HIV strategy, which aims to virtually eliminate transmission of the virus by 2022.
The TGA approved the once-daily dolutegravir and rilpivirine (Juluca) as a treatment for HIV in July.